Yara International ASA (YAR)
Oslo Børs · Norway · prices in NOK · close of 27 Oct 2026
Key indicators
| Last close | NOK 398.00 |
|---|---|
| 52-week range | 353.40 – 599.40 |
| Return, 1 month / 3 months | −8.1% / −9.1% |
| Return, 1 year / 3 years | +10.6% / +18.9% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 33.6% |
| Worst drawdown (1 year) | -30.5% |
| Average daily value traded | 224.65M NOK |
| Dividend yield | 5.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Yara International is a Norwegian company that makes and supplies crop nutrition products. It produces nitrogen-based mineral fertilizers, including ammonia, urea and nitrate grades, and sells them to farmers and agricultural distributors around the world. The company also supplies industrial products such as technical ammonia and chemicals used in other manufacturing. Its operations span mining, production plants and distribution networks, with its head office in Oslo, Norway, and customers in many farming regions across the globe.
The shares are listed on the Oslo Børs in Norway under the code YAR, and the price on this page is in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Yara International ASA (YAR) trades on the Oslo Børs in Norway. It last closed at NOK 398.00 on 27 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 166 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.6% and over the last three months it fell 9.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Børs
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.6% | ||
| From 52-week high | -33.3% | ||
| Momentum | 37 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.1% | ||
| 6-month return | -22.6% | ||
| 12-month return, skipping the last month | 20.3% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.5% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 224.65M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −1.0% |
|---|---|
| 1 month | −8.1% |
| 3 months | −9.1% |
| 6 months | −22.6% |
| 1 year | +10.6% |
| 3 years | +18.9% |
| 5 years | +27.4% |
Signals
| 50-day / 200-day average | 434.04 / 460.54 |
|---|---|
| Golden / death cross (60 days) | Death, 52 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 10.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 May 2026 | NOK 22.0000 |
| 30 May 2025 | NOK 5.0000 |
| 29 May 2024 | NOK 5.0000 |
| 13 Jun 2023 | NOK 55.0000 |
| 7 Dec 2022 | NOK 10.0000 |
| 11 May 2022 | NOK 30.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Børs; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.